A Decade of Legislative Stagnation
Access to medication remains an unresolved failure of Chile’s healthcare system, exacerbated by a legislative paralysis that has dragged on for over a decade. As reported by the news outlet El Mostrador, the bill known as 'Fármacos II,' which aims to make medicines more accessible to the public, has yet to be passed since it was first introduced in March 2015.
This situation highlights an anomaly in the country’s healthcare spending. According to an analysis published by El Mostrador, total health expenditure in Chile has climbed from 4% of GDP in 1990 to nearly 10% today—a figure comparable to the OECD average. However, while public spending has risen from 1.9% to nearly 6% of GDP, out-of-pocket spending—the money people pay directly when facing illness—has stubbornly remained above 30% of total health expenditure. Medications are the primary driver of these costs, accounting for more than a third of that household burden.
Structural Failures and Policy Priorities
El Mostrador attributes this crisis to a combination of structural issues that the country has failed to address. An rapidly aging population has placed immense pressure on the system, yet Chile has failed to make the necessary investments in prevention or adapt its care network to the chronic diseases that now dominate the country’s epidemiological profile.
These issues are compounded by inefficiencies in both the public and private sectors. In the public sector, productivity has failed to take off despite sustained increases in funding. In the private sector, the outlet argues that current incentives run counter to keeping the population healthy and containing costs, as they prioritize higher service volumes and increased consumption over preventative health.
The report notes that explicit health guarantees and the supplies available in primary care are currently insufficient to meet the massive public demand. The lack of legislative progress sends a clear message about the country’s political priorities after eleven years of debate.
The article concludes that this delay reflects how "industry interests and the inability to reach political consensus have, systematically, been more powerful than the common good." Consequently, the outlet argues that access to medication remains a vicious cycle that Chile cannot seem to break, even as the issue periodically returns to the public discourse as if it were a new discovery.
